Wednesday, October 14, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 25, 2026

T-Mobile Turns up the Value With the Samsung Galaxy S26 Lineup

View original at finance.yahoo.com
T-Mobile Turns up the Value With the Samsung Galaxy S26 Lineup Samsung’s newest Galaxy devices land at T-Mobile — with on Us offers, benefits worth switching for and a five-year price guarantee Get 5G Home Internet delivered same-day and bundle with a new Galaxy S26 for even more savings BELLEVUE, Wash., February 25, 2…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • SuperMobile is the best business plan on the best network

    80% confidence

  • Combined with built-in benefits and a 5-year price guarantee on best plans, T-Mobile offers unmatched performance and value not found anywhere else

    80% confidence

  • T-Mobile's 5G network provides quicker uploads and downloads for large files and smooth 4K streaming even in crowded places like airports and events

    80% confidence

  • This is T-Mobile's richest Galaxy offer ever and the first time T-Mobile customers can get the Galaxy S26 Ultra on Us

    80% confidence

  • T-Mobile's 5G Advanced network unlocks the full performance of the Galaxy S26, turning features like multi-carrier aggregation and uplink enhancements into noticeable real-world improvements in speed, responsiveness and reliability

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
T-Mobile Turns up the Value With the Samsung Galaxy S26 Lineup — Source | Via News | Finance Via News